Jens Lindqvist is a fully-qualified medical doctor from Karolinska Institute (Sweden) with 20 years of capital markets experience in London. At N+1 Singer, Jens spent more than 10 years evaluating public and private equity in the UK life sciences sector, as well as originating mandates and helping to raise funds.
Brough Ransom also joins from N+1 Singer, where he was a specialist salesperson responsible for promoting healthcare stocks to investors and raising money for IPOs and secondary fundraisings. He has spent 22 years in the sector at a variety of institutions including Merrill Lynch, ING and Nomura.
Jens and Brough will work alongside healthcare analyst Andrew Whitney as well as Daniel Adams and Gary Clarence, who lead Investec’s healthcare advisory offering. Current Investec healthcare clients include Dechra Pharmaceuticals, Advanced Medical Solutions Group and Alliance Pharma.
Harold Hutchinson, Head of Research, commented:
"Jens and Brough bring considerable depth to Investec’s healthcare offering, with many years of experience in healthcare equity research and sales.”
“We see a particular opportunity for further growth in biotech and pharmaceuticals, building on our existing success across the healthcare sector. We believe that these hires – together with our top-ranked generalist sales and trading platforms – give us the strongest offering in the sector.”